Quadrant Capital Group’s X4 Pharmaceuticals XFOR Stock Holding History

Quadrant Capital Group’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-128	Closed	-$529	–	2616
2026 Q1	$529	Buy	+128	New	+$479	﹤0.01%	2630

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quadrant Capital Group's XFOR Position: Q2 2026 in Review

Quadrant Capital Group sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 128 shares — an estimated $529 sold.

Quadrant Capital Group first reported a position in XFOR in Q1 2026 and held it in 1 quarter. The position peaked at $529 in Q1 2026. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Quadrant Capital Group reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 128 X4 Pharmaceuticals shares in Q2 2026, an estimated $529.
Quadrant Capital Group first reported a position in X4 Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Quadrant Capital Group's X4 Pharmaceuticals position peaked at $529 in Q1 2026.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.